about
Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazolePharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision MedicineLansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer PhenotypePhenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals.CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus.The role of trefoil factor family in apparently healthy subjects administrated gastroprotective agents for the primary prevention of gastrointestinal injuries from low-dose acetylsalicylic acid: a preliminary study.A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease.Independent and combined effects of environmental factors and CYP2C19 polymorphisms on the risk of esophageal squamous cell carcinoma in Fujian Province of China.Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes.Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality?Genotype and allele frequency of CYP2C19*17 in a healthy Iranian populationThe effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized MedicineTreatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic.How May Proton Pump Inhibitors Impair Cardiovascular Health?Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics.Functional polymorphisms in the CYP2C19 gene contribute to digestive system cancer risk: evidence from 11,042 subjects.Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy.CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapyClopidogrel pharmacogenetics: metabolism and drug interactions.Acid peptic diseases: pharmacological approach to treatment.Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.A benefit-risk assessment of the use of proton pump inhibitors in the elderly.Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel.Histology of symptomatic gastroesophageal reflux disease: is it predictive of response to proton pump inhibitors?A Case of Refractory Gastric Cardia Ulcer in Which Marked Elevation of the Surrounding Mucosa was Observed During the Clinical Course.Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom ReseEfficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine.Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients.Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors.Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease.Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases.Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study.
P2860
Q26741015-7C7BA218-210D-47CD-A22C-AE5EE1EF2C6AQ27692687-89CF3F3C-F8E0-4CD5-84E8-61D1D5B3D76AQ30300235-299AA798-DD2B-4B74-A4E1-EDEAFB069B2BQ33290485-B8A2268C-0609-407D-89D1-9C80451A9A6BQ33368192-D9441053-823C-4B08-9150-22CA90E2F228Q33445961-DD22705E-F556-49F3-9022-908F957150A7Q34774061-C7C51331-D8EE-435F-B34F-7726D19F45D3Q35116562-D4D55D30-532F-4F2A-B862-36FC15E597D1Q35209641-2133071E-5833-4E27-8A77-64ADE6F590A0Q35308159-D0303DD9-E6C7-417C-9CD3-3B7A40226869Q35576753-83460F61-37E1-4A54-B7AA-462093C5E384Q35873680-DD391C14-6BD0-470D-A33A-5684F39702DAQ35873687-A3E0A269-A4F8-4C23-B894-278483D5853BQ36278015-7E152650-DCB2-40BF-B7D2-4D6268A840C4Q36469405-ADCBC8FF-B6EF-48F0-B8A1-DE4342DAB871Q36545135-80ABCEA7-BEBA-41C2-BACD-1F8B2422C38AQ36580034-6CD2F5E2-E06C-4DE4-9457-EE6298C48299Q36723844-67411D95-587B-4F7F-8B9D-DCE2E5878EE4Q36892867-1495AF69-5D03-4FC4-A1E2-9B56F10945CCQ36979297-796D9799-CBA8-4226-896B-AC4037E4709DQ37017860-08D985C2-6D69-41EE-A9AD-DA97A4D5B7D4Q37176949-F4B69ED3-78F6-4827-A903-02D2CBA1388EQ37646785-F3D0BEE0-B7E1-4002-AAE2-3C09E3923046Q37714369-E179B283-8B06-4323-AA8F-3ABBFB7C8E04Q37912178-C30ED3A9-559C-4159-8499-6C0F22E7EB4DQ37913063-C2C4F592-7630-43B4-AA3D-B2676488B922Q38032920-EBE99885-FE0B-4AD0-A642-F6C05BA8CDC7Q38196383-D57C79A5-C89C-4A07-B368-1625B15CBFCFQ39014375-102DF80A-0937-41D1-BFC9-F3DCD1E2B2B5Q39241665-5E7636E9-6B9F-429E-9C78-7C2BD0DC125DQ39245665-ACF729ED-7480-48ED-B7EF-8D5D89BBE3BBQ39260588-AC338A8C-3C0D-4079-B18C-4ED75D844A0EQ39496607-278647EB-7943-4357-8E29-53566894C650Q39543475-FE978C5B-3311-433F-99FE-80D8B80C6610Q41642334-0B24B3CD-B66F-4BA1-BEB0-0E307C55D354Q41706384-ADDC47EE-8F35-407C-BE8B-4DA8E4731580Q42424894-07790EC2-5B98-49A0-BDD6-03883ECBD76EQ42608396-D5E77C45-85A2-4138-AD49-CCF7AC4D9297Q42731681-BACA8C7F-DD66-41F5-9F2D-5265EECD6A28Q42961046-C0D9B462-967D-4D78-82AE-E208BEC723E4
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pharmacogenomics of proton pump inhibitors.
@ast
Pharmacogenomics of proton pump inhibitors.
@en
type
label
Pharmacogenomics of proton pump inhibitors.
@ast
Pharmacogenomics of proton pump inhibitors.
@en
prefLabel
Pharmacogenomics of proton pump inhibitors.
@ast
Pharmacogenomics of proton pump inhibitors.
@en
P2093
P2860
P1433
P1476
Pharmacogenomics of proton pump inhibitors.
@en
P2093
Kyoichi Ohashi
Mitsushige Sugimoto
Naohito Shirai
Takahisa Furuta
Takashi Ishizaki
P2860
P304
P356
10.1517/PHGS.5.2.181.27483
P577
2004-03-01T00:00:00Z